18F-氟脱氧葡萄糖PET/CT影像组学联合临床特征预测肺腺癌表皮生长因子受体突变
该回顾性研究纳入179例肺腺癌患者,按7:3随机分为训练集125例和测试集54例,从PET和CT图像提取2632个影像组学特征,构建临床联合影像组学模型预测EGFR突变,训练集AUROC为0.882、准确率81.6%,测试集AUROC为0.837、准确率74.1%;在99例亚组中区分19外显子缺失与21外显子L858R突变的影像组学模型训练集AUROC为0.708、准确率66.7%,测试集AUROC为0.652、准确率56.7%。
要点
- 临床联合PET/CT影像组学模型预测EGFR突变状态具有中等准确度,训练集AUROC 0.882、测试集0.837
- 仅用PET/CT影像组学区分EGFR 19外显子缺失与21外显子L858R突变较困难,测试集AUROC仅0.652
- 联合模型纳入性别、吸烟史、肿瘤直径和影像组学评分,训练集准确率81.6%、测试集74.1%
核心结论
- 临床联合PET/CT影像组学模型能以中等准确度识别肺腺癌EGFR突变状态,但用PET/CT影像组学区分EGFR 19外显子缺失与21外显子L858R突变亚型更具挑战性。
研究设计与样本
- 回顾性分析179例肺腺癌患者,按7:3随机分为训练集125例和测试集54例,从PET和CT图像感兴趣区各提取1316个影像组学特征(共2632个),经特征选择保留6个PET/CT影像组学特征计算影像组学评分,并结合性别、吸烟史、肿瘤直径构建临床联合影像组学模型,用ROC曲线评估性能。
诊断标准与关键数值
- 临床联合PET/CT影像组学模型识别EGFR突变的AUROC和准确率在训练集分别为0.882和81.6%,在测试集分别为0.837和74.1%;区分19外显子缺失与21外显子L858R突变的PET/CT影像组学模型(99例亚组)AUROC和准确率在训练集分别为0.708和66.7%,在测试集分别为0.652和56.7%。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To identify epidermal growth factor receptor (EGFR) mutations in lung adenocarcinoma based on 18F-fluorodeoxyglucose (FDG) PET/CT radiomics and clinical features and to distinguish EGFR exon 19 deletion (19 del) and exon 21 L858R missense (21 L858R) mutations using FDG PET/CT radiomics.
MATERIALS AND METHODS: We retrospectively analyzed 179 patients with lung adenocarcinoma. They were randomly assigned to training (n = 125) and testing (n = 54) cohorts in a 7:3 ratio. A total of 2632 radiomics features were extracted from the tumor region of interest from the PET (1316) and CT (1316) images. Six PET/CT radiomics features that remained after the feature selection step were used to calculate the radiomics model score (rad-score). Subsequently, a combined clinical and radiomics model was constructed based on sex, smoking history, tumor diameter, and rad-score. The performance of the combined model in identifying EGFR mutations was assessed using a receiver operating characteristic (ROC) curve. Furthermore, in a subsample of 99 patients, a PET/CT radiomics model for distinguishing 19 del and 21 L858R EGFR mutational subtypes was established, and its performance was evaluated.
RESULTS: The area under the ROC curve (AUROC) and accuracy of the combined clinical and PET/CT radiomics models were 0.882 and 81.6%, respectively, in the training cohort and 0.837 and 74.1%, respectively, in the testing cohort. The AUROC and accuracy of the radiomics model for distinguishing between 19 del and 21 L858R EGFR mutational subtypes were 0.708 and 66.7%, respectively, in the training cohort and 0.652 and 56.7%, respectively, in the testing cohort.
CONCLUSION: The combined clinical and PET/CT radiomics model could identify the EGFR mutational status in lung adenocarcinoma with moderate accuracy. However, distinguishing between EGFR 19 del and 21 L858R mutational subtypes was more challenging using PET/CT radiomics.
引用
- Li S, Li Y, Zhao M, et al. Combination of 18F-Fluorodeoxyglucose PET/CT Radiomics and Clinical Features for Predicting Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma. Korean J Radiol. 2022. PMID: 36047542. doi:10.3348/kjr.2022.0295
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。